ADA Highlights

flipper_slider

Editor's Choice

Chantal Mathieu discusses the outcomes of the EMPA-REG, LEADER and SUSTAIN-6 trials on diabetes treatment. Part 1 of 2 View Part 2 here.

ADA Highlights Videos

Stefano Del Prato discusses the use of DPP-4 inhibitors and vildagliptin in special patient populations. Read more in European Endocrinology here. Support: The filming of this video was supported by Novartis. Stefano Del Prato has received research support from AstraZeneca, MSD, Novartis and...
W David Strain and Päivi Maria Paldánius discuss the post-authorisation programme for vildagliptin and clinical evidence for the optimised management of chronic diseases beyond type 2 diabetes. Read more in European Endocrinology here. Support: The filming of this video was supported by Novartis...
Bo Ahrén and James Foley discuss the Initiation of the Novartis GLP-1 based therapy programme the development of vildagliptin over the past 10 years. Read more about it in European Endocrinology here. Support: The filming of this video was supported by Novartis. James Foley is an employee and...
Chantal Mathieu and Päivi Maria Paldánius discuss the development pathway of DPP-4 inhibitors and vildaglipin. Read more in the recent publication in European Endocrinology here. Support:The filming of this video was supported by Novartis. Päivi Maria Paldánius is an employee of Novartis....
Nick Oliver discusses the access to continuous glucose monitoring in the UK, and the challenges faced by patients and physicians. View the recent article in European Endocrinology here. Disclosures: The filming of this video is supported by Dexcom.
Claudia Graham discusses the place of continuous glucose monitoring outside of the US. View the recent article in European Endocrinology here. Disclosures: Claudia Graham is an employee of Dexcom. The filming of this video is supported by Dexcom.
James Foley and Bo Ahren review the development of DPP-4 inhibitors, including vildagliptin over the past 25 years.
Baptist Gallwitz discusses the unmet need and recent developments in type 2 diabetes at ADA 2017. The filming of this interview was supported by AstraZeneca.
Baptist Gallwitz discusses the key findings from the EMPA-REG and CPD-Real studies for patients with type 2 diabetes. The filming of this interview was supported by AstraZeneca.
Silvio Inzucchi discusses the recent CV and renal data highlights from EMPA REG OUTCOME. The filming of this interview was supported by Boehringer Ingelheim.
Silvio Inzucchi shares his highlights from ADA 2017.
W David Strain and Päivi Maria Paldánius talk about the changing paradigms in the treatment and investigation into type 2 diabetes.
Chantal Mathieu discusses how the role of insulin therapy in diabetes is likely to change in coming years. Part 2 of 2 View Part 1 here.
Chantal Mathieu discusses the outcomes of the EMPA-REG, LEADER and SUSTAIN-6 trials on diabetes treatment. Part 1 of 2 View Part 2 here.
Nick Oliver, Wynn Professor of Metabolism Imperial College, London, UK discusses which presentations and/or data highlighted at the ADA 2017 interested him the most.